Sugi Predict

Sugi Predict / Compounds / SCHEMBL320207

SCHEMBL320207

SCHEMBL320207

O=C(O)c1ccnc(-c2c(F)cccc2F)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.47
▸ ALOX15 P16050 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ ACMSD Q8TDX5 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ TTR P02766 1/20 0.46
▸ KDM5A P29375 2/20 0.44
▸ KDM3A Q9Y4C1 2/20 0.44
▸ JMJD1C Q15652 1/20 0.44
▸ KDM6B O15054 1/20 0.41
▸ TET3 O43151 1/20 0.41
▸ KDM4A O75164 1/20 0.41
▸ BBOX1 O75936 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ KDM5C P41229 1/20 0.41
▸ ASPH Q12797 1/20 0.41
▸ KDM4D Q6B0I6 1/20 0.41
▸ TET2 Q6N021 1/20 0.41
▸ ALKBH5 Q6P6C2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21271882 0.86 MAP4K1 (0.55) MAP4K1NTRK1MAP4K2STK4
SCHEMBL29572632 0.86 MAP4K1 (0.55) MAP4K1NTRK1MAP4K2STK4
SCHEMBL30879644 0.85 PIM1 (0.42) TTRPIM1PIM3PIM2MAP4K1
SCHEMBL24383681 0.82 MAP4K1 (0.43) KDM4CKMT2AMAP4K1XDHNTRK1
SCHEMBL1505808 0.80 KDM4E (0.57) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL26058396 0.79 MAP4K1 (0.38) KDM4EKDM5AKDM3AJMJD1CKDM6B
SCHEMBL21296074 0.76 XDH (0.36) KDM4EKDM5AKDM3AJMJD1CKDM6B
SCHEMBL21309140 0.76 XDH (0.35) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL696116 0.75 XDH (0.50) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL28988552 0.75 XDH (0.56) KDM4EKDM5AKDM3AJMJD1CMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11866426-B2 Benzothiazole compounds and uses thereof INCYTE CORPORATION (US) 2024-01-09 — — US disclosed
US-11299473-B2 Benzimidazole and indole compounds and uses thereof INCYTE CORPORATION (US) 2022-04-12 — — US disclosed
CN-112794860-B Oxazole pyrimidone amide compound or medicinal salt thereof, preparation method and application 上海肇钰医药科技有限公司 2021-06-29 — — CN disclosed
US-20210171518-A1 BENZOTHIAZOLE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2021-06-10 — — US disclosed
US-20210171518-A1 BENZOTHIAZOLE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2021-06-10 — — US disclosed
CN-112794860-A Oxazole pyrimidone amide compound or medicinal salt thereof, preparation method and application 上海肇钰医药科技有限公司 2021-05-14 — — CN disclosed
US-10899755-B2 Benzothiazole compounds and uses thereof INCYTE CORPORATION (US) 2021-01-26 — — US disclosed
US-20200048241-A1 BENZOTHIAZOLE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-02-13 — — US disclosed
US-20200048241-A1 BENZOTHIAZOLE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-02-13 — — US disclosed
US-20190315717-A1 BENZIMIDAZOLE AND INDOLE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-10-17 — — US disclosed
US-20130109682-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS NOVARTIS AG (CH) 2013-05-02 — — US disclosed
US-20130109682-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS NOVARTIS AG (CH) 2013-05-02 — — US disclosed
US-20130109682-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS NOVARTIS AG (CH) 2013-05-02 — — US disclosed
CN-103080106-A Cyclic ether compounds useful as kinase inhibitors NOVARTIS AG 2013-05-01 — — CN disclosed
WO-2012120415-A1 TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2012-09-13 — — WO disclosed
WO-2012120415-A1 TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2012-09-13 — — WO disclosed
US-20120225061-A1 TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2012-09-06 — — US disclosed
US-20120225061-A1 TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2012-09-06 — — US disclosed
US-20120225061-A1 TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2012-09-06 — — US disclosed
WO-2012004217-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11299473-B2 Benzimidazole and indole compounds and uses thereof PGK1, PDXK, HIPK1 KDM4E 2852/4885ALOX15 1987/4885TSHR 4712/4885
US-20190315717-A1 BENZIMIDAZOLE AND INDOLE COMPOUNDS AND USES THEREOF PGK1, PDXK, HIPK1 KDM4E 2852/4885ALOX15 1987/4885TSHR 4712/4885
US-10899755-B2 Benzothiazole compounds and uses thereof PDXK, PCK1, HIPK1 KDM4E 2770/4885ALOX15 1906/4885TSHR 4802/4885
US-20130109682-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS PIM1, GSK3A, GSK3B KDM4E 636/4885ALOX15 4473/4885TSHR 4240/4885
US-20210171518-A1 BENZOTHIAZOLE COMPOUNDS AND USES THEREOF PDXK, PCK1, HIPK1 KDM4E 2770/4885ALOX15 1906/4885TSHR 4802/4885
US-20200048241-A1 BENZOTHIAZOLE COMPOUNDS AND USES THEREOF PDXK, PCK1, HIPK1 KDM4E 2770/4885ALOX15 1906/4885TSHR 4802/4885
US-11866426-B2 Benzothiazole compounds and uses thereof PDXK, PCK1, HIPK1 KDM4E 2770/4885ALOX15 1906/4885TSHR 4802/4885
US-20120225061-A1 TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS PIM1, PIM2, PIM3 KDM4E 1008/4885ALOX15 4620/4885TSHR 3502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.